2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. CDK

CDK

Cyclin dependent kinase

CDK

Related Products

PDF 1.19 MB

CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.

There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.

CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).

CDK Isoform Specific Products:

CDK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-170815
    CDK4/9-IN-1
    		Inhibitor
    CDK4/9-IN-1 (Compound 29) is a selective dual CDK4/9 inhibitor with IC50 values of 23 nM and 12 nM, respectively. CDK4/9-IN-1 is promising for research of cancers.
    CDK4/9-IN-1
  • HY-143430
    (S)-LY3177833
    		Inhibitor
    (S)-LY3177833 ((S)-Example 2) is an orally active CDC7 kinase inhibitor. (S)-LY3177833 shows broad in vitro anticancer activity.
    (S)-LY3177833
  • HY-175842
    CDK2 degrader 7
    		Degrader
    CDK2 degrader 7 is an orally active CDK2 degrader, with DC50 values of 13 nM (MKN1cells) and 17 nM (TOV21G cells). CDK2 degrader 7 induces G1 phase arrest in MKN1 cells. CDK2 degrader 7 achieves tumor stasis in HCC1569 (CCNE1-amplified) xenograft models. CDK2 degrader 7 can be used for the study of CCNE1-amplified cancers.
    CDK2 degrader 7
  • HY-168444
    CDK4/6-IN-23
    		Inhibitor
    CDK4/6-IN-23 (Compound 42) is a potent and selective CDK4/6 inhibitor, with an IC50 of 11 nM for CDK6. CDK4/6-IN-23 can significantly activate immune cells and promote the production of IL-3. CDK4/6-IN-23 has dual myeloprotective and immunomodulatory effects in 5-FU (HY-90006) chemotherapy mice.
    CDK4/6-IN-23
  • HY-E70690
    CDK8/CycC Recombinant Human Active Protein Kinase
    CDK8 modulates the transcriptional output from distinct transcription factors involved in oncogenic control, including the Wnt/β-catenin pathway, Notch, p53, and transforming growth factor β. Abnormal activity ofCDK8 along with its partner protein cyclin C (CycC) is a common feature of many diseases including colorectal cancer. CDK8/CycC Recombinant Human Active Protein Kinase can be used to study the function of CDK8/CycC.
    CDK8/CycC Recombinant Human Active Protein Kinase
  • HY-163357
    CDK2/MDM2-IN-1
    		Inhibitor
    CDK2/MDM2-IN-1 (III-13) is a dual inhibitor of CDK2/MDM2 with an IC50 value of 2.60 nM for CDK2. CDK2/MDM2-IN-1 has antitumor activity.
    CDK2/MDM2-IN-1
  • HY-147387
    DSS30
    		Inhibitor
    DSS30 is a P25/CDK5 inhibitor that reduces β-amyloid (Aβ) secretion by inhibiting amyloid precursor protein lyase 1 (BACEl) phosphorylation. DSS30 can be used in the study of neurodegenerative diseases such as Alzheimer's disease.
    DSS30
  • HY-RS02380
    CDK3 Human Pre-designed siRNA Set A
    		Inhibitor

    CDK3 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    CDK3 Human Pre-designed siRNA Set A
  • HY-156115
    EGFR/CDK2-IN-3
    		Inhibitor
    EGFR/CDK2-IN-3 (compound 4b) is a dual inhibitor of EGFR and CDK-2 with IC50s of 71.7 and 113.7 nM, respectively. EGFR/CDK2-IN-3 induces apoptosis in MCF-7 cells and arrests the cell cycle in the S phase. EGFR/CDK2-IN-3 has significant anti-cancer cell toxicity and inhibits MCF-7 with an IC50 of 3.16 μM.
    EGFR/CDK2-IN-3
  • HY-168620
    CDK6-IN-1
    		Inhibitor
    CDK6-IN-1 (compound 4i) is a CDK6 inhibitor. CDK6-IN-1 inhibits cell growth and induces cell cycle arrest at G1-phase.
    CDK6-IN-1
  • HY-169633
    CDK8-IN-17
    		Inhibitor
    CDK8-IN-17 (Compound WS-2) is a CDK8 inhibitor with an IC50 value of 9 nM, which can be used in cancer research.
    CDK8-IN-17
  • HY-168846
    CDK8/19-IN-3
    		Inhibitor
    CDK8/19-IN-3 (compound 3-7) is a potent and selective CDK8 and CDK19 inhibitor. CDK8/19-IN-3 upregulates IL-10 levels. CDK8/19-IN-3 has the potential for the research of inflammatory bowel disease (IBD).
    CDK8/19-IN-3
  • HY-150573
    CDK2-IN-12
    		Inhibitor
    CDK2-IN-12 (compound 10b) is a potent CDK2 inhibitor, with an IC50 of 11.6 μM. CDK2-IN-12 inhibits hCA (carbonic anhydrase) isoforms I, II, IX and XII, with KI values of 3534, 638.4, 44.3, and 48.8 nM. CDK2-IN-12 shows anticancer activity.
    CDK2-IN-12
  • HY-E70687
    CDK6/CycD2 Recombinant Human Active Protein Kinase
    CDK6 is a cell-cycle kinases that regulate exit from the G1 phase of the cell cycle. CDK6 is directly involved in transcription in tumor cells and in hematopoietic stem cells. CDK6/CycD2 Recombinant Human Active Protein Kinase is an ortholog of CDK6.
    CDK6/CycD2 Recombinant Human Active Protein Kinase
  • HY-179023
    CDK9-IN-45
    		Inhibitor
    CDK9-IN-45 (Compound B11) is a highly selective CDK9 inhibitor with IC50 values for CDK9 and CDK1 of 7.13 and 489.5 nM respectively. CDK9-IN-45 exhibits a potent inhibitory effect on colorectal cancer cells. CDK9-IN-45 induces cell apoptosis and leads to significant accumulation of ROS. CDK9-IN-45 activates Caspase-3, downregulates Mcl-1, XIAP, and c-Myc. CDK9-IN-45 can be used for research on colorectal cancer.
    CDK9-IN-45
  • HY-160171
    CDK9-IN-31
    		Inhibitor
    CDK9-IN-31 (Compound Z1) is a CDK9 inhibitor that inhibits cancer cell growth. CDK9-IN-31 has the potential to be developed as an anticancer agent.
    CDK9-IN-31
  • HY-132914
    CDK/HDAC-IN-1
    		Inhibitor
    CDK/HDAC-IN-1 shows remarkable CDK2/4/6 and HDAC6 inhibitory activity of IC50 = 60.9 ± 2.9, 276 ± 22.3, 27.2 ± 4.2, and 128.6 ± 0.4 nM, respectively.
    CDK/HDAC-IN-1
  • HY-178227
    KY19334
    		Inhibitor
    KY19334 is a CXXC5-DVL inhibitor. KY19334 can activate the Wnt/β-catenin pathway by inhibiting CXXC5-Dvl interaction. KY19334 can inhibit cancer cells proliferation, migration, invasion and transformation by inhibiting CDK1. KY19334 can accelerate wound healing and exert regenerative effects. KY19334 can be used for the researches of cancer, inflammation, metabolic and neurological disease, such as cutaneous squamous cell carcinoma and diabetes.
    KY19334
  • HY-145424
    CDK7-IN-10
    		Inhibitor
    CDK7-IN-10 is a CDK7 inhibitor with an IC50 of less than 100 nM, extracted from patent WO2021016388A1, compound I-1. CDK7-IN-10 is useful in inhibiting the activity of a kinase. CDK7-IN-10 has the potential of inhibiting cell growth and inducing cell apoptosis.
    CDK7-IN-10
  • HY-172582
    CDK9-IN-38
    		Inhibitor
    CDK9-IN-38 (compound 14) is a CDK9 inhibitor with IC50 values of 1.2 nM and 3.3 nM for CDK9 wild-type and L156F mutant, respectively. CDK9-IN-38 inhibits tumor growth in vivo and in vitro.
    CDK9-IN-38
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
CDK Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.